Modality.AI
@ModalityAI
Followers
65
Following
15
Statuses
149
Today, during the annual "JPM Week" in San Francisco, CEO, David “DSO” Suendermann-Oeft, PhD participated in a panel discussion "What is TechBio and What Impact Will It Have on Therapeutic Development?"
0
0
0
Curious about what it takes to build a startup at the intersection of AI and medicine? Our visionary CEO, David “DSO” Suendermann-Oeft, PhD, shares his rich tapestry of roles as researcher, professor, founder, scientist, and musician...
0
0
0
This week, our Chief Operating Officer, Lakshmi Arbatti, and Data Scientist, Abhishek Hosamath, presented their work at the Parkinson Study Group Annual Meeting in Tennessee. #pd #Parkinsons #ClinicalTrials
0
0
1
Modality Presents at Parkinson Study Group Annual Meeting: This week, our COO, Lakshmi Arbatti, and Data Scientist, Abhishek Hosamath, are presenting their work at the Parkinson Study Group Annual Meeting in Tennessee.
0
0
0
Modality’s CEO David "DSO" Suendermann-Oeft and Senior Research Scientist Hardik Kothare to present our work on "Multimodal Speech Biomarkers for Remote Monitoring of ALS Disease Progression" at the 7th Annual ALS Research Symposium.
0
0
0
@TargetALS_fdn, the global foundation for ALS research, is partnering with to launch a groundbreaking direct-to-participant study.
0
0
0
*Five New ALS Publication Acceptances* At ALS remains at the very heart of our mission, so we're pleased to share that our research has recently been recognized with five new presentations at three seminal ALS conferences.
0
0
0
@TargetALS_fdn is partnering with to launch a groundbreaking direct-to-participant study, utilizing Modality's innovative digital health platform to monitor disease progression in ALS patients.
0
0
0
Attending the International Congress of Parkinson's Disease and Movement Disorders®? We invite you to connect with Modality's Head of Science Sales, Meredith Bartlett.
0
0
0
You're invited to our next webinar, Digital Biomarkers in CNS Trials - on Friday, September 27 at 10 AM PT.
0
0
0
New Publication: Multimodal Technologies for Remote Assessment of Neurological and Mental Health. The article reviews the advantages of using multimodal technologies for remote neurological and mental health assessment. #ClinicalTrials
0
0
0
How can we capture a fuller picture of patient experiences in clinical trials? Find out now through this recording of a recent Modality webinar in which we discuss the Patient Report of Problems.
0
0
0
Modality will present four papers at the premier speech conference Interspeech 2024, taking place in Greece September 1–5.
0
1
1
Our CEO, David Suendermann-Oeft, will attend the Digital Biomarkers in Clinical Trials Summit on June 26, 2024, at Roche Headquarters in Basel. Be sure to connect if you’re attending.
0
0
0
Modality CEO David "DSO" Suendermann-Oeft interviewed by BioNews.
0
0
0
David will present two posters at ENCALS https://modality.ai/publications
#ALS #clinicalresearch #clinicaltrials
0
0
1
Will you be at #BIO in San Diego? Let's meet! Our CEO, David Suendermann-Oeft (DSO) is sharing an update on on Wednesday, June 5th at 2.45pm in Presentation Room 4. DSO will also present on Thursday afternoon in the NIH booth. #BIOInternationalConvention
0
0
1